THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN ...

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is ...

Investors need to pay close attention to Harmonic (HLIT) stock based on the movements in the options market lately.

Robot actuators must generate high torques, but at the same time be light and compact. The ideal application for the Harmonic ...

Third Harmonic Bio, Inc. ( (THRD) ) has released its Q3 earnings. Here is a breakdown of the information Third Harmonic Bio, Inc. presented to ...

Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, ...

Q3 2024 Earnings Call Transcript October 29, 2024 Operator: Welcome to the Third Quarter 2024 Harmonic Earnings Conference ...

The Harmonic Drive is a key part of countless robotic applications. Incredibly simple yet quite odd to watch, this gear system is extremely precise with an impressive torque-to-weight ratio, even if ...

Harmonic Inc. reports strong Q3 results but faces concerns, leading to a cautious outlook. Click for more on HLIT Stock and its most recent earnings release.

Harmonic (NASDAQ:HLIT – Get Free Report) was downgraded by Raymond James from a “strong-buy” rating to an “outperform” rating ...

Fintel reports that on October 29, 2024, Jefferies downgraded their outlook for Harmonic (NasdaqGS:HLIT) from Buy to Hold.

Research analysts at Northland Capmk raised their FY2024 earnings per share (EPS) estimates for Harmonic in a report issued ...